Press Releases

Key Highlights from 2024: Patients: Invested €829 million in R&D; opened Parma Biotech Center of Excellence; Health Equity initiatives now active in 33 countries; expanded efforts to improve access to neonatal treatments in low-income countries. Planet: Published Climate Transition Plan reinforcing commitment to reaching Net Zero Emissions by 2035; renewed the EcoVadis Platinum Medal, placing in the top 1% of companies globally; 6 Chiesi laboratories certified with “My Green Lab” at highest level. People: 7,542[1]employees of which 17% were new hires; named among the World’s 25 Best Workplaces™; corporate volunteering involved 40% of workforce completing 15,400 hours (+53%). Prosperity: Updated Code of Interdependence in collaboration with suppliers; Chiesi Headquarters obtained ISOs for Anti-bribery and Information Security.     Parma, June 4h, 2025 – Chiesi, the international R&D-focused biopharmaceutical group headquartered in Parma, Italy, with 31 affiliates worldwide, has published its 2024 Sustainability Report, reaffirming its long-term commitment to responsible business practices through substantial investments and measurable progress across four key areas of impact: Patients, Planet, People, and Prosperity.   Chiesi, as a Benefit Corporation and certified B Corp, is committed to measuring, improving, and transparently reporting its social and environmental impact. Since 2017, the company has published a voluntary Sustainability Report in accordance with the Global Reporting Initiative (GRI) standards—internationally recognized guidelines that ensure credible and comparable sustainability reporting. In 2019, Chiesi achieved B Corp certification, demonstrating a clear focus on rigorous measurement and continuous progress. In 2024, Chiesi finalized the preparation for the upcoming re-certification, scheduled for 2025.   The company emphasizes the importance of harmonized reporting standards and accountability as drivers of long-term societal and economic progress. For this reason, Chiesi is working in anticipation of the European Corporate Sustainability Reporting Directive (CSRD) and maintains voluntary assurance of its Sustainability Report. The company is strategically enhancing its data collection and reporting processes to ensure that financial and sustainability disclosures are treated with equal importance, fostering greater integration and alignment between the two.   Giuseppe Accogli, CEO of Chiesi Group, commented on the Sustainability Report:   “2024 was a year of evolution for Chiesi. We welcomed over 1,200 new employees, resulting in a net increase of 524 roles. We reorganized parts of our company and further increased our investment in people and innovation. But more importantly, it was a year in which we reaffirmed our purpose: to generate a positive impact for the patients and the communities we serve. Staying true to this purpose means making bold choices—like hugely investing in R&D, strengthening our commitment to sustainability, and ensuring transparency through rigorous reporting standards. We distributed 84% of the economic value generated to our stakeholders, a measure of how our company contributes economically to its ecosystem. At the same time, 16% of the generated value was retained by the company to further invest in innovation and people’s wellbeing. At Chiesi, purpose drives everything we do—and impact follows. That’s why we will continue to act with decisiveness, measure our progress with transparency, and lead with the conviction that a healthier, fair and sustainable future is not just possible—it is essential to our mission.”   Maria Paola Chiesi, Vice Chair at Chiesi Group commented:   “At Chiesi, sustainability is the way we do business. Our purpose drives us to create lasting positive impact for patients, people, while respecting the planet. Every choice we make must reflect our commitment to improved care, innovation, and health equity. The Sustainability Report is not just a record of our progress—it’s a promise to keep going, to keep improving, and to always act with boldness and transparency. We are building a future where doing good and doing well reinforce one another, and where progress is measured by the impact we have on people’s lives.”   Patients at the Heart: Chiesi’s Global Commitment to Innovation and Care   In 2024, Chiesi reaffirmed its commitment to a patient-centric approach by investing a record €829 million—24.3% of its revenues—into research and development, consolidating its position as Italy’s leading pharmaceutical company for R&D investment. Over the course of the year, Chiesi filed 33 new patent applications with the European Patent Office, contributing to a global portfolio of more than 5,500 patents—tangible evidence of its focus on innovation for the benefit of patients worldwide.   A key milestone of the year was the opening of the Parma Biotech Center of Excellence, a new integrated hub for research and production. Backed by a €400 million investment planned through 2030, the center is set to accelerate the patients’ access to innovative medicines and enhance Europe’s competitiveness in the global biopharmaceutical landscape.   Promoting Health Equity, defined as the absence of unfair and avoidable disparities in health among population groups, is a priority for Chiesi. In line with the UN Sustainable Development Goals—particularly SDG 3 (Good Health and Well-Being) and SDG 10 (Reduced Inequalities)—the Group now promotes health equity initiatives in 33 countries, through close collaboration with partners. At the same time, Chiesi continued to expand the global footprint of its therapies and products, with at least one registration across 130 nations in 2024.   In addition, Chiesi’s Global Health team, dedicated to expanding access to life-saving neonatal treatments in Sub-Saharan Africa, made significant progress in navigating the regulatory drug approval processes in Ethiopia, Tanzania, and Uganda. In parallel with these efforts, the independent non-profit Chiesi Foundation, which celebrates its 20th anniversary in 2025, is devoted to improving quality of care in underserved regions. In neonatal health, the Foundation further developed the NEST (Neonatal Essential Survival Technology) model—active in five West African countries—to reduce newborn mortality. In the field of respiratory health, the GASP (Global Access to Sustainable Pulmonology) project supported the diagnosis and management of chronic respiratory diseases in Guyana, Nepal, and Peru. These programs exemplify the Group’s broader commitment to advancing equitable healthcare—not only through innovation, but through action.   A Plan for the Planet: A Year of Environmental Milestones at Chiesi   In 2024, Chiesi took a decisive step forward in its journey to Net Zero greenhouse gas (GHG) emissions by 2035 by publishing its first Climate Transition Plan. The Plan outlines a structured governance model to address climate change, detailing emissions reduction strategies across Scopes 1, 2, and 3, alongside financial planning, risk mitigation, and transparent performance metrics. That same year, Chiesi’s Net Zero targets received official validation from the Science Based Targets initiative (SBTi), underscoring the Group’s commitment to credible and science-aligned climate action. In 2025 Chiesi is publishing an updated version of its Climate Transition Plan, further strengthening its roadmap to reaching Net Zero.   Significant progress has already been made. Compared to the 2019 baseline, in 2024 Scope 1 emissions were reduced by 27%, mainly due to reduction in car fleet, propellant and stationary emissions and Scope 2 market-based emissions by an 97%, due to the purchased electricity coming from renewable sources. Notably, 99% of the electricity used across Chiesi’s global sites now comes from renewable sources, with 100% of purchased electricity in Italy supplied through a long-term Power Purchase Agreement (PPA) with a solar plant.   Efforts to improve energy efficiency have delivered tangible results. Total energy consumption across the organization fell by 2% compared to 2023. At the same time, the share of energy derived from renewable sources rose to 46%—up from 42% of the previous year.   The Group is also advancing in sustainable mobility: by the end of 2024, about 31% of the company car fleet consisted of electric and hybrid vehicles, supporting a broader goal to cut fleet-related emissions by 90% by 2030.   As for Scope 3 emissions, while they increased in the last five years—largely driven by a rise in the use of sold-product-emissions category linked to the growth in metered-dose-inhalers sales—the Group made progress in terms of emission intensity. When measured against revenue, Chiesi’s GHG emission intensity (tons of CO₂eq per million euros of revenue) declined by approximately 7.5% from 2023 to 2024.   Innovation plays a critical role in Chiesi’s environmental strategy. A cornerstone project is the development of next-generation, carbon-minimal inhaler products. Backed by an investment of over €350 million, the current propellant will be replaced in Chiesis's pressurized metered dose inhaler (pMDI) products with a much lower global warming potential propellant—reducing the inhaler’s carbon footprint by up to 90%. With the transition to carbon-minimal inhaler products, while still supporting Dry Powder Inhaler (DPI) technology, Chiesi will provide patients with a variety of treatment options tailored to their individual needs.    Beyond product innovation, Chiesi is raising environmental standards across its entire value chain. In 2024, the Group updated its Code of Interdependence in collaboration with its suppliers, a guiding document that promotes responsible sourcing and higher environmental and social standards among suppliers. Today, around 70% of Chiesi’s annual strategic spend is with suppliers who have signed the Code. The Group also improved its EcoVadis sustainability rating, retaining the Platinum Medal and ranking in the top 1% of companies assessed globally for performance across Environment, Ethics, Human Rights, and Procurement.   Environmental sustainability also extends into Chiesi’s scientific research. In partnership with My Green Lab, the leading global standard for sustainable lab practices, six of the Group’s laboratories achieved Green-level certification—the highest recognition available. At least four more labs are expected to follow in 2025.   Where People Thrive: From Gender Balance to Global Volunteering   In 2024, Chiesi Group continued to grow as a global organization, reaching a total of 7,542 employees—a net increase of 524 compared to the previous year. The Group’s workforce remains well balanced, with women representing 57% of the total population and 58% of new hires. Notably, 27% of new hires were under the age of 30, reflecting Chiesi’s commitment to attracting young talent and building a future-ready workforce.   Chiesi reached a significant milestone that year: it was named one of the World's 25 Best Workplaces™ by Great Place To Work® and Fortune. As the first Italian company ever recognized, this honor reflects Chiesi’s enduring commitment to a fair and supportive workplace.   Advancing gender justice remained a key focus in 2024, with progress on two fronts: equal pay and equal career opportunities. Chiesi first achieved gender pay equity in 2022 and continues to monitor and manage the unexplained pay gap, which as of 2024 remains below 1% and not statistically significant. Progress was also made toward achieving balanced gender representation in leadership. The Group reached gender parity at the middle-management level and remains committed to extending this balance across all senior leadership roles by 2028.   Beyond the workplace, Chiesi significantly increased its investment in social impact initiatives. In 2024, the Group allocated €29.7 million to support local communities, patients, and scientific research, including the donation of over 80,500 units of Chiesi medicines—valued at €9.9 million[2].   Corporate volunteering also saw a meaningful rise in engagement. A total of 15,368 volunteer hours were recorded in 2024—up 53% from the previous year—with 40% of Chiesi employees actively participating in community service projects.     Prosperity with Purpose: Chiesi’s Model for Sustainable Impact   At Chiesi, prosperity means long-term value creation for patients, people, communities, and the planet. Guided by the principle “Do Good, Do Well, Repeat”, the Group embraces a Shared Value approach to business: by developing solutions that generate positive societal and environmental impact (Do good), Chiesi achieves sustainable growth (Do well), reinvesting resources to drive further innovation and impact (Repeat).   This commitment is embedded in a governance model based on ethics, transparency, and accountability, which ensures that the company’s actions align with its common benefit goals and corporate values. In 2024, Chiesi updated its Code of Conduct, reflecting the Group’s evolution and its enduring commitment to human rights and sustainable business practices—consistently with its legal form as a Benefit Corporation in Italy, the U.S., France and Colombia.   Chiesi Headquarters also strengthened its organizational integrity and resilience through key ISO certifications, obtaining both the Anti-Bribery Management System and the Information Security Management System certifications in 2024. These milestones reinforce the Group’s focus on responsible management and operational excellence.     For detailed insights, the full 2024 Sustainability Report is available here: www.chiesi.com     About Chiesi Group   Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. By adopting the legal form of Benefit Corporation in Italy, the US, France and Colombia, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,500 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden. For further information please visit www.chiesi.com     Press Info:   Laura Vergani, Senior Vice President, Global Communications & Public Affairs: mediarelations@chiesi.com   Michela Lijoi, Global External Communications Sr. Manager: mobile +39 328.6353044, e-mail: m.lijoi@chiesi.com   Davide Paterlini, Global External Communications Sr. Manager: mobile +39 345.7983132, e-mail: d.paterlini@chiesi.com     [1] The total of employees in the Sustainability Report includes long-term employee absences and therefore differs from the total of employees reported in the Consolidated Financial Statement (7,065 at December 31st 2024) which excludes long-term employee absences. It also differs from the total workforce mentioned here (7,542 at December 31st 2024) in which external collaborators (field force contractors and ad interim employees) of the Group are included while long-term employee absences are also excluded.   [2] The amount donated is based on the average annual market price of the donated product. This amount represents the closest approximation of the actual cost that the customer would have had to contribute to purchase the product in the marketplace and therefore differs from the standard cost of the product reported in the Group’s financial statements.

Nazareth, Israel and Parma, Italy, June 05, 2025 – Elgan Pharma Ltd. and Chiesi Farmaceutici S.p.A today announced the dosing of the first participating infants in FIT-PIV, a Phase 3 clinical study to assess the efficacy and safety of ELGN-2112, an investigational drug candidate for treatment of intestinal malabsorption in preterm infants, a frequent condition associated with life threatening complications.      “We are thrilled to launch the FIT-PIV trial, with ELGN-2112, which we hope will improve outcomes for premature infants," said Miki Olshansky, Founder and CEO of Elgan Pharma. "Elgan Pharma is dedicated to developing therapies for preterm infants, targeting their unique unmet medical needs. Together with our partners at Chiesi, we are committed to improve the outcomes and care of premature infants."   “The enrollment of the first infant patients in this study is critical to our innovation in neonatology,” said Diego Ardigò, Executive Vice President, Global Research & Development, Chiesi Group. “Addressing intestinal malabsorption in preterm infants demonstrates Chiesi's ever-evolving approach to rare and emerging medical needs. With over decades of experience in neonatology, Chiesi remains committed to improving care for premature born babies.”   About the FIT-PIV Study The FIT-PIV study is a Phase 3 pivotal, multi-center, double-blind, randomized, two-arm, parallel-group, placebo-controlled study, designed to assess the efficacy and safety of ELGN-2112 on intestinal malabsorption in preterm infants. The study is designed to enroll 420 infants, born in 26-32 weeks and weighing at least 500g. The study is expected to open in approximately 50 sites in the United Kingdom, Europe, Israel and the United States. The FIT-PIV study is part of a comprehensive clinical development plan that includes additional studies.   The primary endpoint of the study is the number of days to achieve full enteral feeding (FEF), which is a milestone associated with reduction of risks of complications. Reaching FEF earlier means faster and more efficient development of the infant’s GI tract. Babies treated with ELGN-2112 in previous trials, including a first phase 3, have previously reached their nutrition goals earlier , their time on parenteral nutrition (PN) was shorter and had fewer complications.[1],[2] For additional information, please visit:  https://clinicaltrials.gov/study/NCT05670951?term=FIT%20PIV&rank=1   About ELGN-2112 ELGN-2112 is a proprietary formulation of recombinant human insulin tailored for neonatal use, delivered enterally and compatible with infants' nutrition. ELGN-2112 is expected to improve gastrointestinal function, increase absorptive surface area and enhance adaptation, thereby reducing the need for intravenous feeding and decreasing the risk of associated complications. Based on its consistent positive results shown across several clinical trials to date, ELGN-2112 can potentially become an important therapy for premature infants.   The novel formulation results in a highly soluble insulin powder for reconstitution, which allows for accurate, low doses, appropriate for preterm babies. It is compatible with all infant nutrition including mother’s own milk, donor breast milk and infant formulas and contributes to gut rehabilitation with no systemic exposure to insulin.[3]   Insulin is naturally present in amniotic fluid and breast milk during the first few days of life. There is evidence from studies that insulin has important physiological effects on intestinal growth, cell maturation, and enzyme expression and therefore improves the ability of the intestine to absorb nutrition. Upon birth, a newborn infant’s gastrointestinal tract is exposed to insulin via colostrum (breast milk in the first days of life). Importantly, in utero the gastrointestinal tract also exposed to the insulin present in amniotic fluid and consumed by the fetus, resulting in a constant influx of insulin stimulating the gastrointestinal tract. Insulin is one of mother nature’s tools for maturing an infant gastrointestinal tract for independence. [4],[5],[6],[7],[8],[9]     About Intestinal Malabsorption in Preterm Infants Intestinal malabsorption in preterm infants is a rare medical condition characterized by an underdeveloped gastrointestinal tract, leading to the inability to adequately absorb and tolerate the enteral nutrition necessary for proper overall growth, neurological development, and development of the gastrointestinal tract itself. These infants are dependent on parenteral nutrition for fluid and nutrition needs. The combination of a poorly functioning gastrointestinal tract and dependency on parenteral nutrition puts this vulnerable infant population at risk for life-threatening complications, such as necrotizing enterocolitis, and compromises long-term health and neurological developmental outcomes. Accelerating the transition to enteral nutrition is a major goal for preterm infants in the neonatal intensive care unit suffering from intestinal malabsorption.   Gastrointestinal complications can also lead to longer hospitalization and an increased burden for healthcare systems.     About Elgan Pharma Elgan Pharma is a late-stage clinical stage, neonatology-focused biotechnology company, dedicated to developing safe, tailored therapies to address medical complications and developmental challenges that are common in preterm infants. The company is advancing multiple promising clinical-stage and preclinical investigational therapeutics. For further information, please visit www.elganpharma.com     About Chiesi Group Chiesi is research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.   By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.   With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,000 employees. The Group’s research and development center in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden. For further information please visit www.chiesi.com     Contacts for Media:     Elgan Pharma Tsipi Haitovsky Global Media Liaison +972-52-598-9892 pr@elganpharma.com   Chiesi Group Anja Ivic Communications Manager +31615961711 a.ivic@chiesi.com   PP-CA-00213 V2.0   [1] Mank E, Sáenz de Pipaón M, Lapillonne A, Carnielli VP, Senterre T, Shamir R, van Toledo L, van Goudoever JB; FIT-04 Study Group. Efficacy and Safety of Enteral Recombinant Human Insulin in Preterm Infants: A Randomized Clinical Trial. JAMA Pediatr. 2022 May 1;176(5):452-460 [2] Shehadeh, N et al. Efficacy and Safety of Enteral Recombinant Human Insulin for Reduction of Time-to-Full Enteral Feeding in Preterm Infants: A Randomized, Double-blind, Placebo-Controlled Trial. IMAJ vol. 23,9 (2021): 563-568 [3] Mank E, Sáenz de Pipaón M, Lapillonne A, Carnielli VP, Senterre T, Shamir R, van Toledo L, van Goudoever JB; FIT-04 Study Group. Efficacy and Safety of Enteral Recombinant Human Insulin in Preterm Infants: A Randomized Clinical Trial. JAMA Pediatr. 2022 May 1;176(5):452-460 [4] Neu, J.; Li, N. The Neonatal Gastrointestinal Tract: Developmental Anatomy, Physiology, and Clinical Implications. Neoreviews 2003, 4, e7–e13 [5] Shulman, R J. Oral insulin increases small intestinal mass and disaccharidase activity in the newborn miniature pig. Pediatric research vol. 28,2 (1990): 171-5 [6] Shulman, R J et al. Effect of oral insulin on lactase activity, mRNA, and posttranscriptional processing in the newborn pig. Journal of pediatric gastroenterology and nutrition vol. 14,2 (1992): 166-72 [7] Shehadeh, N et al. Importance of insulin content in infant diet: suggestion for a new infant formula. Acta Pediatr 2001;90:93–95 [8] Ben Lulu, Shani et al. Oral insulin stimulates intestinal epithelial cell turnover in correlation with insulin-receptor expression along the villus-crypt axis in a rat model of short bowel syndrome. Pediatric surgery international vol. 26,1 (2010): 37-44 [9] Vas et al. Insulin, Testosterone, and Albumin in Term and Preterm Breast Milk, Donor Milk, and Infant Formula. Nutrients 2023;15:1476

HIGHLIGHTS €3.4 billion revenues, up 13% at constant exchange rates (CER) compared to 2023 Record R&D investment of €829 million (24.3% of revenues) Profitability close to 30% for the fifth consecutive year Air franchise: revenues of €1.8 billion, a growth of 7.2%% (CER). Fastest growing company product (fixed triple combination inhaler for asthma and COPD patients) hits 35% sales growth Rare disease business unit: revenues of €763 million (up 41%, CER), representing 22% of total Group sales Care franchise: revenues of €818 million, up 6% (CER)   Parma (Italy), April 16th, 2025 – Chiesi, an international research-oriented biopharmaceutical group headquartered in Parma, Italy, with commercial affiliates in 31 countries, closed 2024 with strong financial results, reaffirming its trajectory of sustainable, long-term growth with a strong commitment to fostering R&D and innovation.   Revenues reached €3,413 million, marking a 13% increase at CER compared to 2023. EBITDA was just over €1 billion, up 12%, with a margin close to 30%.   Chiesi Group’s net profit totaled €493 million, and its positive net financial position (cash minus financial liabilities including leasing) reached €535 million.   Giuseppe Accogli, CEO of Chiesi Group, commented on the results: “Chiesi Group delivered an impressive performance, making 2024 the third consecutive year of double-digit growth. These results highlight the positive impact of our clear strategy, our innovative, comprehensive and diversified product portfolio, and strong international footprint. Our performance was further accelerated by the successful implementation of the new operating model, designed to drive positive impact for Patients, Planet, People, and Prosperity. This, combined with our outstanding operational excellence, strong internal talent and company culture, gives us confidence that we are firmly on track to meet our ambitious goals of mid- to high-single digit sales growth over the next five years. Our prospects are strong, thanks to the focus on our own existing pipeline with 43 projects, external collaboration push, and significant investments in manufacturing, such as the Biotech Center of Excellence and the newly acquired production site in Nerviano.”   GEOGRAPHICAL DISTRIBUTION In 2024, the Group recorded revenue growth across all markets in which it operates. Europe remained the highest contributor, accounting for 64% of total revenues (led by UK, Spain, and France) and registering approximately 10% growth in absolute terms. The Group achieved particularly strong results in the U.S., which is now the largest single-country market by revenue at 20% of total turnover, and with approximately 24% increase in absolute terms.  China also delivered an impressive 22% growth at CER.     THERAPEUTIC AREAS The Air franchise, which includes products and services for the treatment of respiratory diseases, remained the primary therapeutic area for Chiesi, accounting for €1,832 million - 54% of total revenue. The fixed-triple combination for the treatment of asthma and COPD grew 35% year-on-year. The Carbon-Minimal Inhaler program to reformulate Chiesi's inhaler products with a new, low-carbon propellant, made significant progress. Phase III clinical trials were initiated to support the introduction of Chiesi's respiratory products into the U.S. market. Chiesi also entered into a collaboration with U.S.-based Gossamer Bio to develop a treatment for Pulmonary Arterial Hypertension (PAH) and pulmonary hypertension associated with interstitial lung diseases (PH-ILD).   The Care franchise accounted for €818 million - 24% of the Group's revenue. To further strengthen its commitment to supporting the most vulnerable patients, Chiesi continued the collaboration with U.S. biotech company Oak Hill Bio, launched in 2023, with the enrollment of the first patient in a Phase IIb clinical study for a new experimental drug to treat complications of extreme prematurity.   The Global Rare Diseases business unit had revenues of €763 million (up 41%), driven by the full integration of Amryt Pharma, acquired in 2023, and the launch of three new products in the U.S. market, following FDA approvals received in the previous year. This represents 22% of revenue (a 4% increase year-on-year) and is one of the Group’s key strategic development areas.     R&D, PARTNERSHIPS, AND PRODUCTION INVESTMENTS In 2024, R&D spending reached a record €829 million (24.3% of revenue), an increase from €721 million in the previous year. This growth was primarily driven by Phase III clinical trials for the entry of respiratory products into the U.S. market and the strategic expansion of the pipeline across all therapeutic areas. According to the JRC EU Industrial R&D Investment Scoreboard 2024, Chiesi remained the top pharmaceutical company in Italy for R&D investments and the 11th in Europe.   Chiesi also filed 33 new patent applications with the European Patent Office (EPO) in 2024, a testament to the strategic importance of R&D.   In September 2024, the Group inaugurated its Biotech Center of Excellence in Parma, with a total investment of €380 million planned between 2024 and 2030, which will also enhance the competitiveness of Italy and Europe in the global biopharmaceutical sector.   PEOPLE In 2024, Chiesi Group created over 500 new roles, and increased its workforce by 7.6% workforce compared to the previous year, reaching a total of 7,542 employees globally.   The Group also continued to invest in internal talent development, promoting its Human Leadership model and enhancing succession pipelines. Chiesi’s dedication to fostering a positive workplace culture was recognised by Great Place to Work and Fortune magazine, with the company placing on their 25-strong World’s Best Workplaces list - the only European pharmaceutical company and the first-ever Italian company to achieve this.     PLANET In 2024, Chiesi made significant strides in its journey to combating climate change and promoting sustainability, with the approval of its greenhouse gas (GHG) emissions reduction targets by the Science Based Targets Initiative (SBTi). Chiesi also increased its EcoVadis rating, confirming the Platinum Medal and ranking among the top 1% of companies worldwide for outstanding performance in Environment, Ethics, Labor and Human Rights, and Sustainable Procurement. The Group has committed to achieving Net Zero Emissions by 2030 for direct emissions (Scopes 1 and 2) and by 2035 for all indirect emissions (Scope 3).     OUTLOOK 2025   According to Giuseppe Accogli, CEO of Chiesi Group: “In 2025, Chiesi aims to continue to grow by mid-single digits, and achieve strong cash flow generation and a solid financial position. This will enable us to further boost our future growth, via significant investments in innovation, acceleration in external partnerships and potential acquisitions to expand our portfolio and pipeline across all development stages. Our goal is to never leave any patients behind, and improve their quality of life by providing advanced therapeutic solutions and expanding production capacity to meet increasing product volumes required.”   About Chiesi Group Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.   By changing its legal status to a Benefit Corporation in Italy, the US, France and Colombia, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.   With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,500 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.   Media Contacts:   Chiesi Group Laura Vergani, Senior Vice President, Global Communications & Public Affairs e-mail: mediarelations@chiesi.com   Davide Paterlini, Global External Communications Sr. Manager mobile +39 345.7983132, e-mail: d.paterlini@chiesi.com  

The project is part of the Group’s industrial plan to support its global growth The site will specialize in the production of sterile biological products, DPI and carbon minimal inhalers for the treatment of respiratory diseases, with a primary focus on the latter The redevelopment of the facility and its surrounding area will be centered on innovation and sustainability criteria   Milan, March 27th, 2025 – Chiesi Group, a global biopharmaceutical company headquartered in Parma, Italy, has announced a major investment in Nerviano (Milan, Italy), with the construction of a new facility for the production of its therapeutic solutions. The project entails the revitalization of this historical production site, first established in 1965 as an oncology research centre for Farmitalia Carlo Erba and subsequently subjected to several ownership changes, until its closure in 2024. The facility will be primarily dedicated to manufacturing carbon minimal inhalers, reinforcing the company’s commitment to both patients’ health and sustainable healthcare solutions. Dry powder inhalers and sterile biological products will also be developed in Nerviano. The €430 million investment, spread between 2025 and 2030, will fund the redevelopment of a 124,000-square-meter industrial area, transforming it into an international center of excellence. This initiative is part of the Group’s global industrial strategy, which includes ongoing investments in its facilities in Parma (Italy) and Blois (France) and operations in Santana de Parnaíba (Brazil) to meet the growing needs of people living with respiratory conditions. The objective is to support the company’s growth and its goal of achieving Net Zero emissions by 2035.   The redevelopment will modernize the existing site, originally built in the 1980s, turning it into a next-generation production center. Once fully operational, the site will feature over 3,000 square meters of laboratory space and a photovoltaic park with an installed capacity sufficient to ensure the plant's energy self-sufficiency. Adjacent to the industrial facility, a 20,000-square-meter wooded area will undergo a regeneration project.   Beyond its environmental and technological advancements, the investment will deliver tangible benefits to the local community. The site is expected to create approximately 300 new jobs by 2029, stimulating economic growth in the region.   "We chose Nerviano for its strategic location and the potential of the industrial area, which we will transform into a center of excellence for the production of next-generation inhalers," said Giuseppe Accogli, CEO of Chiesi Group. "This investment strengthens our presence in Italy and Europe, consolidates our leadership in the sector, and creates new growth opportunities for the local community. It also complements our significant investments in the Parma area, notably our recent Biotech Center launch."     About Chiesi Group Chiesi is research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.   By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.   With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.     Contacts for Media:   Gruppo Chiesi Laura Vergani, Senior Vice President, Global Communications & Public Affairs e-mail: mediarelations@chiesi.com   Davide Paterlini, Global External Communications Sr. Manager mobile +39 345.7983132, e-mail: d.paterlini@chiesi.com

Chiesi Group appoints Roch Doliveux, Paolo Pucci, and Daphne Quimi to further enhance Board capabilities and internationalize leadership These senior business leaders bring diverse expertise and international experience, strengthening governance and international best practices, whilst supporting Chiesi's global ambitions New committees established: Governance, Nomination and Compensation; Audit and Risk; Strategy, Sustainability and Innovation   Parma, January 29th, 2025 – Chiesi, the international research-focused biopharmaceutical Group, announces the appointment of three new independent Non-Executive Directors (NEDs) to its Board: Roch Doliveux, Paolo Pucci and Daphne Quimi. Following a global search, the new Board members have joined the current five at Chiesi, effective January 28th, 2025.   The addition of three new NEDs is a significant part of Chiesi's broader strategy to enhance the Board’s capabilities, focusing on both upskilling and further internationalizing its leadership.   Driven by the continued foresight of the Chiesi family, this step represents a clear advancement in the company's efforts to enrich corporate governance as part of its ongoing international and patient impact growth. The new NEDs bring valuable expertise that will guide the company towards industry best practices.   By fostering diversity and introducing new competencies, they will support Chiesi’s commitment to sustainable growth, organizational transition, and international expansion, including into the important US market.   Furthermore, with the inclusion of these new members, Chiesi has also improved its Board functionality, particularly through the establishment of internal committees designed to enhance decision-making processes. The new committees are set up as follows: Governance, Nomination and Compensation Committee: Roch Doliveux (Chairperson), Maria Paola Chiesi, Daphne Quimi, Alessandro Chiesi Audit and Risk Committee: Daphne Quimi (Chairperson), Giacomo Chiesi, Paolo Pucci, Andrea Chiesi Strategy, Sustainability and Innovation Committee: Paolo Pucci (Chairperson), Maria Paola Chiesi, Roch Doliveux, Andrea Chiesi Each of the new Board members brings extensive experience to support Chiesi adapt to the rapidly evolving marketplace and continue its evolution:   Roch Doliveux has extensive leadership experience in Biopharmaceuticals and was CEO of UCB for ten years. He chairs the Boards of Pierre Fabre SA and Oxford Biomedica.   Paolo Pucci has had a distinguished career in the pharmaceutical industry. He served as CEO of ArQule, leading it until its acquisition by Merck & Co. in 2020, and he held senior roles at Bayer Schering Pharma. He serves on the Boards of Replimune Group, Merus and West Pharmaceutical Services.   Daphne Quimi has made significant contributions to the pharmaceutical industry.  As CFO at Amicus Therapeutics, she oversaw IT and facilities during its international expansion. She also held senior roles at Johnson & Johnson, Bristol-Myers Squibb and Avon. She serves on the Boards of Amylyx Pharmaceuticals and Century Therapeutics.   “We are thrilled to welcome Roch Doliveux, Paolo Pucci, and Daphne Quimi to our Board”, says Alessandro Chiesi, Chair. “Their experiences will enhance Chiesi’s governance and support our global ambitions. In line with our family’s vision, this move further reflects our commitment to constant improvement, and will allow us to even better focus on the strategic drivers of our company. It will benefit the Group as we continue to grow and internationalize, and we look forward to the positive impact they will bring.”   “I am confident Roch, Paolo, and Daphne will be excellent additions to the Chiesi Board,” says Giuseppe Accogli, CEO. “They all bring extensive international experience and diverse expertise, which will enhance our competitiveness. Their fresh perspectives and valuable skills will enrich our Board discussions, and strengthen our governance framework, which will help to unlock our potential to improve and develop as a company.”   About Chiesi Group Chiesi is research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.   By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.   With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.   For further information please visit www.chiesi.com   About the new Non-Executive Directors: Roch Doliveux has driven innovation and growth in healthcare through various leadership roles. He facilitated collaboration in medical research as Chairman of the Innovative Medicines Initiative and GLG Institute Healthcare. His previous NED roles included UCB and Stryker (USA). Currently, he chairs the Boards of Pierre Fabre Group and Oxford Biomedica, where he continues to contribute to advancing healthcare and mental health initiatives. Doliveux is a Swiss national.   Paolo Pucci has had a distinguished career in the pharmaceutical industry. He served as CEO of ARQULE, leading it until its acquisition by Merck & Co. in 2020. At Bayer Schering Pharma, he held senior roles, including President of Global Oncology. His tenure at Eli Lilly included leadership positions in Sweden and Italy. Pucci also has extensive NED experience, serving on the Boards of companies like Merus NV, Tarus Therapeutics, and Replimune Group. Pucci is a dual US-Italian national.   Daphne Quimi has made significant contributions to the pharmaceutical industry. As CFO at Amicus Therapeutics, she oversaw IT and facilities during its international expansion. With 13 years at Johnson & Johnson, she gained extensive experience in audit, FP&A, and reporting. She serves on the boards of Amylyx Pharmaceuticals and Century Therapeutics, playing key roles in IPOs, acquisitions and CEO transitions. Quimi is a US national.

Chiesi is the only European pharmaceutical company and the first Italian company ever to be included in the World’s Best Workplaces™ The accolade reflects Chiesi's dedication to people’s well-being, continuous improvement, and creating a positive work environment Chiesi was also recently ranked in in the Best Workplaces in Europe™ 2024, Best Workplaces for Women™ in Greater China, and UK's Best Workplaces in BioPharma™, among others   Parma (Italy) November 14, 2024 – Chiesi Group, an international biopharmaceutical company focused on research, has been named one of the 25 World’s Best Workplaces™ in 2024 by Great Place To Work® (GPTW) and Fortune magazine, ranking 23rd on this year’s list. This is the first time that Chiesi has been included in the GPTW global list, standing out as the first Italian company ever to achieve this honor. Headquartered in Parma, Italy, the Group has 31 affiliates worldwide and employs over 7,000 people, 56% of whom are women. More than 1,300 employees are dedicated to R&D.   “We are immensely proud to be the only European pharmaceutical company included in the World's Best Workplaces™ rankings. Being part of such a selective global list of only 25 companies is a source of huge motivation for continuous improvement.” said Giuseppe Accogli, Chief Executive Officer, Chiesi Group. “This placement stems from our firm commitment to our people's well-being, as it reflects their direct feedback and contribution in shaping Chiesi into a place where we all enjoy working. I believe this accolade will further increase our sense of pride and belonging to a company fully dedicated to serving patients around the world in everything we do”.   Great Place To Work® and Fortune’s annual list selects 25 global organizations that participated in Great Place To Work’s employee survey process, with 7.4 million responses received, representing 20 million employees worldwide. To be considered for the list, companies must be identified as outstanding global employers with recognition on at least five Best Workplaces™ lists in Asia, Europe, Latin America, Africa, North America, or Australia during 2023 or early 2024.   Reacting to the result, Giacomo Mazzariello, Chief Human Resources Officer, said, “Our talented global team is the cornerstone of our success. In all our locations around the world, we strive to create an environment where our people feel that Chiesi is their 'Happy Place'. We believe in human-centered leadership, and we are committed to make every voice matter. We strive for every team member to feel empowered to make a difference by bringing their authentic selves to work, implementing policies aiming at a concrete experience of work-life balance, or as we call it, (work-) Life Harmony. From closing the gender pay gap to fostering a culture of well-being and innovation, we’re not just achieving a ranking; we’re working towards an even brighter future. We are aiming to make a stronger, lasting impact together with our existing talents, and the new ones that will join us over time”.   In addition to today’s recognition, in 2024 Chiesi was also ranked as one of the top 10 Best Workplaces in Europe™, and it was recognized by Fortune as one of the Great Places to Work in Biopharma in the U.S., Best Workplaces for Women™ in Greater China, UK's Best Workplaces in BioPharma™, and UK's Best Workplaces for Development™, among other accolades.   About the Fortune World’s Best Workplaces™ Great Place To Work selected the World’s Best Workplaces by gathering and analyzing more than 7.4 million confidential survey responses, representing the experiences of 20 million employees worldwide at Great Place To Work Certified organizations. Organizations are assessed on their efforts to create great workplaces and positively impact people and communities across multiple countries around the world. Companies must have appeared on at least five Best Workplaces lists in Asia, Europe, Latin America, Africa, North America, or Australia during 2023 or early 2024, and have at least 5,000 employees worldwide, with 40% outside of its headquartered country.  Read the full methodology.To be considered, all companies use the Great Place To Work Trust Index™ survey.   To learn more about the Best Workplaces in Europe™ list click here.   About Chiesi Group Chiesi is research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.   By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we’re part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.   With over 85 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.